Sugi Predict

Sugi Predict / Compounds / SCHEMBL283914

SCHEMBL283914

SCHEMBL283914

O=C(O)c1ccc(C(F)(F)F)cc1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.65
▸ ALDH1A1 P00352 3/20 0.65
▸ HPGD P15428 3/20 0.65
▸ HSD17B10 Q99714 2/20 0.65
▸ USP2 O75604 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ GAA P10253 1/20 0.55
▸ CES2 O00748 2/20 0.53
▸ MRGPRX4 Q96LA9 1/20 0.49
▸ SORT1 Q99523 2/20 0.49
▸ PIM1 P11309 1/20 0.49
▸ PIM2 Q9P1W9 1/20 0.49
▸ HTT P42858 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ GRIK1 P39086 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ RXRA P19793 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28119415 0.98 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10USP2
Hydrochloric Acid SCHEMBL6498102 0.98 KDM4E (0.62) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL27637456 0.88 CES2 (0.56) KDM4EALDH1A1HPGDHSD17B10USP2
Heptane SCHEMBL28836076 0.87 RARB (0.58) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL28188798 0.86 GAA (0.57) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL4464473 0.85 KIF11 (0.55) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL5356539 0.85 ALDH1A1 (0.47) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL15917732 0.85 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL10702656 0.84 GAA (0.55) KDM4EALDH1A1HPGDHSD17B10USP2
SCHEMBL29382489 0.84 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 610 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 — — CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
CN-116836081-A Ether epoxy toughening agent and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2023-10-03 — — CN claimed
CN-116283773-A Sinomenine amide derivative, and preparation method and application thereof 安徽农业大学 2023-06-23 — — CN claimed
CN-113880762-B Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof 河北农业大学 2023-02-21 — — CN claimed
CN-113880762-A 1, 8-naphthalimide-containing triacylamine derivatives, and preparation method and application thereof 河北农业大学 2022-01-04 — — CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
CN-107681052-B Main group metal complexes as p-dopants for organic electronic matrix materials 西门子公司 2020-03-24 — — CN claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 — — WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 — — WO claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 KDM4E 1814/4885ALDH1A1 1569/4885HPGD 3145/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 KDM4E 1567/4885ALDH1A1 1723/4885HPGD 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.